Yuling Luo
Co-Founder, Chairman & CEODr. Yuling Luo, Ph.D., is a Venture Partner at Iif Management Company, LLC. He served as Co-Founder and Director of Attovia Therapeutics, Inc. From August 2016 to February 2018 until July 15, 2026, Dr. Luo served as President, Advanced Cell Diagnostics of Bio-Techne Corporation. He is Chairman and Chief Executive Officer of Alamar Biosciences, Inc. since May 2018 and is its Co-Founder. He co-founded Advanced Cell Diagnostics, Inc., in 2008 and served as the President and Chief Executive Officer. He was the inventor of RNAscope, a breakthrough RNA single molecule detection technology. Dr. Luo also co-founded Avida Biomed Inc., where he served as a director from January 2019. Dr. Luo co-founded Panomics (previously Genospectra, Inc.) in 2000 and serves as its Senior Advisor. Dr. Luo served as Group Leader of Gene Expression of Panomics, Inc. At Panomics, Dr. Luo served various roles including Vice President, Functional Genomics and Chief Scientific Officer and he led the development and launch of all of its flagship product lines. Dr. Luo has several years of experience in life science research. Previously he was a Senior Scientist at Exelixis, where he led a team of scientists to identify and validate novel therapeutic targets. Here he developed biochemical and cell-based assays for target validation and compound screening. His expertise encompasses nucleic acid assays, gene expression, gene regulation and mutagenesis, protein structure-function analysis, protein engineering and drug discovery. He serves as a Director of Advanced Cell Diagnostics, Inc. Dr. Luo is an entrepreneur with start-up experience in leadership and innovation. He holds a Ph.D in biochemistry from Case Western Reserve University and conducted post-doctoral research at the University of Pennsylvania. Dr. Luo received his B.S. in Chemistry from the University of Science and Technology of China.
公司職務
- 公司名稱Alamar Biosciences, Inc.股票代碼ALMR職務Co-Founder, Chairman & CEO共事同僚
